Jonathan Symonds Buys 1,550 Shares of GSK (LON:GSK) Stock

GSK plc (LON:GSK) insider Jonathan Symonds purchased 1,550 shares of the company’s stock in a transaction that occurred on Friday, June 19th. The shares were purchased at an average price of GBX 1,935 per share, for a total transaction of £29,992.50.

GSK Stock Up 1.8%

GSK traded up GBX 35.50 during trading on Tuesday, reaching GBX 1,960. The stock had a trading volume of 27,888,139 shares, compared to its average volume of 8,764,782. The stock’s 50 day moving average is GBX 1,955.63 and its two-hundred day moving average is GBX 1,966.35. The company has a current ratio of 0.79, a quick ratio of 0.73 and a debt-to-equity ratio of 106.74. The company has a market capitalization of £78.60 billion, a price-to-earnings ratio of 13.79, a P/E/G ratio of 1.24 and a beta of 0.29. GSK plc has a one year low of GBX 1,288.61 and a one year high of GBX 2,282.

GSK (LON:GSK) last announced its earnings results on Wednesday, April 29th. The company reported GBX 46.50 EPS for the quarter. The firm had revenue of GBX 762.90 billion for the quarter. GSK had a net margin of 17.78% and a return on equity of 35.78%. As a group, analysts expect that GSK plc will post 175.980975 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on GSK shares. Berenberg Bank reaffirmed a “hold” rating and set a GBX 2,000 target price on shares of GSK in a research note on Thursday, March 26th. Jefferies Financial Group restated a “buy” rating and issued a GBX 2,500 price target on shares of GSK in a research note on Thursday, May 28th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a GBX 1,900 price objective on shares of GSK in a research report on Monday, June 8th. Shore Capital Group reiterated a “buy” rating on shares of GSK in a research note on Wednesday, March 25th. Finally, Citigroup reduced their price objective on shares of GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of GBX 2,034.29.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.